Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort

Andres Martinez-Andres Juan; Antonio Garcia-Carmona Juan

首页> 外文期刊>Schizophrenia research >Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort

【24h】

Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort

机译：氯氮平，21世纪的有争议的黄金标准抗精神病药：转向帕利维酮棕榈酸棕榈酸地3-每月改善了代谢型材，并降低了治疗抗性精神分裂症队列中的抗精神剂量等同物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Schizophrenia research》 |2019年第2019期|共3页
作者
Andres Martinez-Andres Juan; Antonio Garcia-Carmona Juan;
展开▼
作者单位

Luis Valenciano Residence Hosp Longstay Unit Psychiat C Lorca 60 Murcia 30120 Spain;

Reina Sofia Univ Hosp Unit Acute Psychiat Murcia Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词

相似文献

外文文献
中文文献

1. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort [J] . Andres Martinez-Andres Juan, Antonio Garcia-Carmona Juan Schizophrenia research . 2019,第期

机译：氯氮平，21世纪的有争议的黄金标准抗精神病药：转向帕利维酮棕榈酸棕榈酸地3-每月改善了代谢型材，并降低了治疗抗性精神分裂症队列中的抗精神剂量等同物
2. A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics [J] . Li Nan, Zhuo Jian Min, Turkoz Ibrahim, Expert opinion on pharmacotherapy . 2019,第13a18期

机译：亚洲患者入院风险的后期分析，精神分裂症切换到一次每月巴黎酮棕榈酸棕榈药
3. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics [J] . Nan Li, Yu Feng, Huafei Lu, Neuropsychiatric Disease and Treatment . 2018,第1期

机译：中国精神分裂症患者每月一次从口服抗精神病药转为帕潘立酮棕榈酸酯后与症状，功能和看护者负担改善相关的因素
4. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study [O] . Miquel Bioque, Eduard Parellada, Clemente García-Rizo, 2020

机译：Clozapine和Paliperidone Palmitate抗精神病药组合在治疗抗性精神分裂症和其他精神病疾病中：回顾性的6个月镜像研究
5. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study [O] . Andreas Schreiner, Asaf Caspi, Paul Bergmans, 2016

机译：非急性精神分裂症患者从口服非典型抗精神病药物单一疗法转为帕潘立酮棕榈酸酯每月一次：一项前瞻性，开放性，干预性研究

Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort

著录项

相似文献

相关主题

期刊订阅